DOI:
10.1055/s-00023610
Drug Research
LinksClose Window
References
Gonem S, Berair R, Singapuri A. et al.
Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet.
Respir Med 2016;
4: 699-707
DOI: 10.1016/S2213-2600(16)30179-5.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.